(0.05%) 5 250.89 points
(0.00%) 39 762 points
(-0.09%) 16 384 points
(1.82%) $82.83
(0.52%) $1.727
(1.25%) $2 240.40
(1.09%) $25.02
(1.42%) $922.60
(0.23%) $0.926
(0.64%) $10.84
(-0.05%) $0.791
(0.12%) $92.55
@ $6.86
Issued: 14 Feb 2024 @ 09:30
Return: -3.21%
Previous signal: Feb 9 - 15:54
Previous signal:
Return: -0.72 %
Live Chart Being Loaded With Signals
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity...
Stats | |
---|---|
Today's Volume | 817 341 |
Average Volume | 824 101 |
Market Cap | 429.29M |
EPS | $0 ( 2024-03-25 ) |
Next earnings date | ( $-0.350 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.23 |
ATR14 | $0.0230 (0.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-10 | Kuriakose Emil | Sell | 0 | Common Stock |
2024-03-10 | Kuriakose Emil | Sell | 280 000 | Stock Option (Right to buy) |
2024-03-10 | Kuriakose Emil | Sell | 117 500 | Stock Option (Right to buy) |
2024-03-01 | Burroughs Amy L. | Buy | 1 250 000 | Stock Option (Right to buy) |
2024-03-01 | Burroughs Amy L. | Buy | 150 000 | Restricted Stock Unit |
INSIDER POWER |
---|
78.48 |
Last 96 transactions |
Buy: 30 047 425 | Sell: 4 951 891 |
Volume Correlation
Terns Pharmaceuticals, Correlation
10 Most Positive Correlations | |
---|---|
SVAC | 0.926 |
EMLD | 0.908 |
ARTEU | 0.905 |
CFFE | 0.905 |
PAIC | 0.898 |
LRMR | 0.898 |
GDST | 0.897 |
ARIZ | 0.896 |
CARG | 0.892 |
LQDA | 0.891 |
10 Most Negative Correlations | |
---|---|
BCAB | -0.929 |
ATAI | -0.923 |
CUTR | -0.923 |
SMFL | -0.92 |
GMAB | -0.919 |
MYSZ | -0.919 |
SRAC | -0.916 |
SPCX | -0.908 |
VFF | -0.906 |
NCBS | -0.903 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Terns Pharmaceuticals, Correlation - Currency/Commodity
Terns Pharmaceuticals, Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-881 000 (0.00 %) |
EPS: | $-1.270 |
Q4 | 2023 |
Revenue: | $0 |
Gross Profit: | $-220 000 (0.00 %) |
EPS: | $-0.290 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-222 000 (0.00 %) |
EPS: | $-0.420 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-217 000 (0.00 %) |
EPS: | $-0.250 |
Financial Reports:
No articles found.
Terns Pharmaceuticals,
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators